Clinical trials: Phase I
Advanced Solid Tumors
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
the main purpose: Evaluate the safety and resistance of BAT6026 injection as a single agent in the treatment of patients with locally advanced or metastatic solid tumors Acceptability Explore maximum tolerated dose (MTD) or…
- Trial name
- NCT05105971
- Testing
- BAT6026
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Bio-Thera Solutions
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, and gemcitabine, work in different ways to stop the growth of tumor…
- Trial name
- NCT00623064
- Testing
- cisplatin, gemcitabine hydrochloride, lapatinib ditosylate
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pathogen Infection, EBV Infection
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients.
- Conditions
- Pathogen Infection, EBV Infection, CMV Infection, Adenovirus Infection
- Trial name
- NCT03159364
- Testing
- pathogen-specific CTLs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Lung Adenocarcinoma, Lung Cancer
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated…
- Conditions
- Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Trial name
- NCT03076164
- Testing
- Trametinib, Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Phase Chronic Myeloid Leukemia
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
This study is designed to determine the maximal tolerated dose of Ruxolitinib in combination with nilotinib in patients with chronic myeloid leukemia (CML).
- Trial name
- NCT01702064
- Testing
- Nilotinib, Ruxolitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Healthy
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV.
- Trial name
- NCT06623409
- Testing
- GARDASIL®9 (G9), V540B
- Where
- 4 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hemorrhagic Fever, Ebola
Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)
The study is designed to establish safety, tolerability and immunogenicity of rVSVΔG-ZEBOV-GP (BPSC1001), an Ebola Virus Vaccine candidate (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of…
- Trial name
- NCT02283099
- Testing
- rVSVΔ-ZEBOV-GP
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Peripheral Arterial Disease, Peripheral Vascular Disease
Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia
The purpose of this study is to evaluate the safety and activity of two doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with chronic critical limb…
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia
- Trial name
- NCT00956332
- Testing
- MultiGeneAngio
- Where
- 7 sites in Israel
- Volunteers
- 28 people
- Sponsor
- MultiGene Vascular Systems Ltd.
Early Stage Breast Cancer
Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA
Radiation, Stereotactic Body Radiation Therapy.
- Trial name
- NCT02685332
- Testing
- Stereotactic Radiation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection
HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong
The goal of this randomized clinical trial is to evaluate the safety and immunogenicity of the HIV Therapeutic DNA Vaccine (ICVAX) in participants with HIV-1 infection under antiretroviral therapy (ART).
- Trial name
- NCT07530198
- Testing
- ICVAX (TERESA-EPT I device), ICVAX (PharmaJet Tropis device), ICVAX (TriGrid device)
- Where
- Hong Kong
- Volunteers
- 22 people
- Sponsor
- Immuno Cure Holding (HK) Limited
Healthy Volunteer
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers
This Phase 1 study is being conducted to evaluate 3 increasing subcutaneous (SC) doses (50, mg, 100 mg or 200mg) of mipomersen in Japanese healthy volunteers.
- Trial name
- NCT01299298
- Testing
- mipomersen
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Advanced KRAS G12D Mutant Solid Tumors
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors.
- Trial name
- NCT07134998
- Testing
- HRS-6093
- Where
- 2 sites in China
- Volunteers
- 153 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignant Tumors
A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.
- Trial name
- NCT07032298
- Testing
- SSGJ-612
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Hemorrhagic Transformation Stroke
Robot-Assisted Hematoma Evacuation With Intrahematoma Tenecteplase for Post-Reperfusion PH2 Hemorrhagic Transformation
The purpose of this phase I trial is to evaluate the safety and feasibility of robot-assisted stereotactic minimally invasive hematoma aspiration, followed when eligible by intrahematoma tenecteplase administration, in patients…
- Trial name
- REPORT (NCT07641998)
- Testing
- Robot-assisted stereotactic hematoma aspiration plus intrahematoma tenecteplase
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Solid Tumours
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.
- Trial name
- NCT00743067
- Testing
- GSK1363089 (formerly XL880)
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Endometrial Cancer, Metastasis
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic.
- Conditions
- Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma
- Trial name
- NCT05542407
- Testing
- Atezolizumab, ONC201
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Systemic Lupus Erythematosus
A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
- Trial name
- NCT03556007
- Testing
- LY3471851
- Where
- 14 sites in United States
- Volunteers
- 48 people
- Sponsor
- Nektar Therapeutics
Group A Streptococcal Infection
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.
- Trial name
- NCT07616934
- Testing
- VAX-A1 Low, VAX-A1 Mid, VAX-A1 High
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.